Analysis of the anticancer activity of curcuminoids, thiotryptophan and 4‑phenoxyphenol derivatives

Parsai,Shireen; Keck,Rick; Skrzypczak‑Jankun,Ewa; Jankun,Jerzy

doi:10.3892/ol.2013.1679

Analysis of the anticancer activity of curcuminoids, thiotryptophan and 4‑phenoxyphenol derivatives

Authors:
- Shireen Parsai
- Rick Keck
- Ewa Skrzypczak‑Jankun
- Jerzy Jankun
View Affiliations

Affiliations: Department of Urology, Urology Research Center, College of Medicine, University of Toledo, Toledo, OH 43614, USA
Published online on: November 12, 2013 https://doi.org/10.3892/ol.2013.1679
Pages: 17-22

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Curcumin, a non‑nutritive yellow pigment derived from the rhizome of Curcuma longa (turmeric), is considered to be an established nutraceutical with anticancer activity. Turmeric contains three principal components, curcumin, demethoxycurcumin and bisdemethoxycurcumin, of which curcumin is most abundant and potent. The concurrence of a high consumption of turmeric and a low incidence of prostate cancer in Asian countries may suggest a role for curcumin in chemoprevention. Curcumin has been identified to exhibit anti‑inflammatory, anti‑oxidative and anticarcinogenic properties. Since the compound does not exhibit side effects, curcumin has been designated for several clinical trials as a treatment for human cancers. The pro‑apototic, antioxidant and anti‑inflammatory characteristics of curcumin are implicated in its anticancer activity, yet the mechanism of action of curcumin remains unknown. To achieve an effective pharmacological outcome, curcumin must reach and sustain appropriate levels at the site of action. However, the main disadvantage of curcumin is its high metabolic instability and poor aqueous solubility that limits its systemic bioavailability. To overcome this difficulty, the present study tested the anticancer activity of new curcumin‑like compounds (E21cH and Q012095H). Also, the use of new medicaments requires an understanding of their pharmacokinetic profiles and targets. Thus, molecular modeling methods were used to identify the targets of curcumin and curcumin‑like compounds compared with other anticancer drugs (Q012138 and Q012169AT), which were used as the controls. The present study identified several enzymes that are targeted by curcumin, aldo‑keto reductase family 1 member B10 (AKR1B10), serine/threonine‑protein kinase, protein kinase C, matrix metalloproteinase (MMP), cyclooxygenase and epidermal growth factor receptor, which were tested as targets for these anticancer chemicals. All the examined small compounds demonstrated anticancer activity in the in vitro experiments and may impact cancer cells by acting on AKR1B10, MMP‑9 and their targets.

View Figures

View References

1	American Cancer Society. Cancer Facts & Figures. 2013, http://www.cancer.org/research/cancerfactsstatistics/index. Accessed March 24, 2013
2	Arcangeli S, Pinzi V and Arcangeli G: Epidemiology of prostate cancer and treatment remarks. World J Radiol. 4:241–246. 2012. View Article : Google Scholar : PubMed/NCBI
3	Cimino S, Sortino G, Favilla V, et al: Polyphenols: key issues involved in chemoprevention of prostate cancer. Oxid Med Cell Longev. 2012:6329592012. View Article : Google Scholar : PubMed/NCBI
4	Fleshner N and Zlotta AR: Prostate cancer prevention: past, present, and future. Cancer. 110:1889–1899. 2007. View Article : Google Scholar : PubMed/NCBI
5	Agrawal DK and Mishra PK: Curcumin and its analogues: potential anticancer agents. Med Res Rev. 30:818–860. 2010.PubMed/NCBI
6	Da-Lozzo EJ, Moledo RC, Faraco CD, Ortolani-Machado CF, Bresolin TM and Silveira JL: Curcumin/xanthan-galactomannan hydrogels: rheological analysis and biocompatibility. Carbohydr Polym. 93:279–284. 2013. View Article : Google Scholar : PubMed/NCBI
7	Hsu CH and Cheng AL: Clinical studies with curcumin. Adv Exp Med Biol. 595:471–480. 2007. View Article : Google Scholar : PubMed/NCBI
8	Park W, Amin AR, Chen ZG and Shin DM: New perspectives of curcumin in cancer prevention. Cancer Prev Res (Phila). 6:387–400. 2013. View Article : Google Scholar : PubMed/NCBI
9	Strimpakos AS and Sharma RA: Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid Redox Signal. 10:511–545. 2008. View Article : Google Scholar : PubMed/NCBI
10	Lin L, Shi Q, Nyarko AK, et al: Antitumor agents. 250. Design and synthesis of new curcumin analogues as potential anti-prostate cancer agents. J Med Chem. 49:3963–3972. 2006. View Article : Google Scholar : PubMed/NCBI
11	Mimeault M and Batra SK: Potential applications of curcumin and its novel synthetic analogs and nanotechnology-based formulations in cancer prevention and therapy. Chin Med. 6:312011. View Article : Google Scholar : PubMed/NCBI
12	Dorai T, Gehani N and Katz A: Therapeutic potential of curcumin in human prostate cancer-I. curcumin induces apoptosis in both androgen-dependent and androgen-independent prostate cancer cells. Prostate Cancer Prostatic Dis. 3:84–93. 2000. View Article : Google Scholar
13	Hatcher H, Planalp R, Cho J, Torti FM and Torti SV: Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci. 65:1631–1652. 2008. View Article : Google Scholar : PubMed/NCBI
14	Shehzad A, Wahid F and Lee YS: Curcumin in cancer chemoprevention: molecular targets, pharmacokinetics, bioavailability, and clinical trials. Arch Pharm (Weinheim). 343:489–499. 2010. View Article : Google Scholar
15	Beevers CS, Chen L, Liu L, Luo Y, Webster NJ and Huang S: Curcumin disrupts the Mammalian target of rapamycin-raptor complex. Cancer Res. 69:1000–1008. 2009. View Article : Google Scholar : PubMed/NCBI
16	Cuendet M and Pezzuto JM: The role of cyclooxygenase and lipoxygenase in cancer chemoprevention. Drug Metabol Drug Interact. 17:109–157. 2000. View Article : Google Scholar : PubMed/NCBI
17	Rao CV: Regulation of COX and LOX by curcumin. Adv Exp Med Biol. 595:213–226. 2007. View Article : Google Scholar : PubMed/NCBI
18	Verderio P, Bonetti P, Colombo M, Pandolfi L and Prosperi D: Intracellular drug release from curcumin-loaded PLGA nanoparticlesinduces G2/M block in breast cancer cells. Biomacromolecules. 14:672–682. 2013. View Article : Google Scholar : PubMed/NCBI
19	Zlotogorski A, Dayan A, Dayan D, Chaushu G, Salo T and Vered M: Nutraceuticals as new treatment approaches for oral cancer - I: Curcumin. Oral Oncol. 49:187–191. 2013. View Article : Google Scholar : PubMed/NCBI
20	Trott O and Olson AJ: AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 31:455–461. 2010.PubMed/NCBI
21	Gallego O, Ruiz FX, Ardèvol A, et al: Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10. Proc Natl Acad Sci USA. 104:20764–20769. 2007. View Article : Google Scholar
22	Liu KK, Bagrodia S, Bailey S, et al: 4-methylpteridinones as orally active and selective PI3K/mTOR dual inhibitors. Bioorg Med Chem Lett. 20:6096–6099. 2010. View Article : Google Scholar : PubMed/NCBI
23	Benes CH, Wu N, Elia AE, Dharia T, Cantley LC and Soltoff SP: The C2 domain of PKCdelta is a phosphotyrosine binding domain. Cell. 121:271–280. 2005. View Article : Google Scholar : PubMed/NCBI
24	Tochowicz A, Maskos K, Huber R, et al: Crystal structures of MMP-9 complexes with five inhibitors: contribution of the flexible Arg424 side-chain to selectivity. J Mol Biol. 371:989–1006. 2007. View Article : Google Scholar
25	Wang JL, Limburg D, Graneto MJ, et al: The novel benzopyran class of selective cyclooxygenase-2 inhibitors. Part 2: the second clinical candidate having a shorter and favorable human half-life. Bioorg Med Chem Lett. 20:7159–7163. 2010. View Article : Google Scholar
26	Yun CH, Boggon TJ, Li Y, et al: Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell. 11:217–227. 2007. View Article : Google Scholar : PubMed/NCBI
27	Bikádi Z, Hazai E, Zsila F and Lockwood SF: Molecular modeling of non-covalent binding of homochiral (3S,3′S)-astaxanthin to matrix metalloproteinase-13 (MMP-13). Bioorg Med Chem. 14:5451–5458. 2006.PubMed/NCBI
28	D’hoedt D and Bertrand D: Nicotinic acetylcholine receptors: an overview on drug discovery. Expert Opin Ther Targets. 13:395–411. 2009.
29	Hetényi C and van der Spoel D: Blind docking of drug-sized compounds to proteins with up to a thousand residues. FEBS Lett. 580:1447–1450. 2006.PubMed/NCBI
30	Iorga B, Herlem D, Barré E and Guillou C: Acetylcholine nicotinic receptors: finding the putative binding site of allosteric modulators using the “blind docking” approach. J Mol Model. 12:366–372. 2006.PubMed/NCBI
31	Seeliger D and de Groot BL: Ligand docking and binding site analysis with PyMOL and Autodock/Vina. J Computb Aided Mol Des. 24:417–422. 2010. View Article : Google Scholar : PubMed/NCBI
32	DeLano WL: The case for open-source software in drug discovery. Drug Discov Today. 10:213–217. 2005.PubMed/NCBI
33	Matsunaga T, Endo S, Soda M, et al: Potent and selective inhibition of the tumor marker AKR1B10 by bisdemethoxycurcumin: probing the active site of the enzyme with molecular modeling and site-directed mutagenesis. Biochem Biophys Res Commun. 389:128–132. 2009. View Article : Google Scholar
34	Balendiran GK: Fibrates in the chemical action of daunorubicin. Curr Cancer Drug Targets. 9:366–369. 2009. View Article : Google Scholar : PubMed/NCBI
35	Xuyu Z, Ruilan Y, Jun M, Duan-Fang L and Deliang C: AKR1B10: A potential target for cancer therapy. Bioscience Hypotheses. 2:31–33. 2009. View Article : Google Scholar
36	Tokunaga C, Yoshino K and Yonezawa K: mTOR integrates amino acid- and energy-sensing pathways. Biochem Biophys Res Commun. 313:443–446. 2004. View Article : Google Scholar : PubMed/NCBI
37	Beevers CS, Zhou H and Huang S: Hitting the golden TORget: curcumin’s effects on mTOR signaling. Anticancer Agents Med Chem. Dec;2012.(epub ahead of print).
38	Deters M, Hütten H and Kaever V: Synergistic immunosuppressive effects of the mTOR inhibitor sirolimus and the phytochemical curcumin. Phytomedicine. 20:120–123. 2013. View Article : Google Scholar
39	Lin JK: Molecular targets of curcumin. Adv Exp Med Biol. 595:227–243. 2007. View Article : Google Scholar : PubMed/NCBI
40	Lou JR, Zhang XX, Zheng J and Ding WQ: Transient metals enhance cytotoxicity of curcumin: potential involvement of the NF-kappaB and mTOR signaling pathways. Anticancer Res. 30:3249–3255. 2010.
41	Conboy L, Foley AG, O’Boyle NM, et al: Curcumin-induced degradation of PKC delta is associated with enhanced dentate NCAM PSA expression and spatial learning in adult and aged Wistar rats. Biochem Pharmacol. 77:1254–1265. 2009. View Article : Google Scholar
42	Tartour E, Pere H, Maillere B, et al: Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer Metastasis Rev. 30:83–95. 2011. View Article : Google Scholar : PubMed/NCBI
43	van Kempen LC and Coussens LM: MMP9 potentiates pulmonary metastasis formation. Cancer Cell. 2:251–252. 2002.PubMed/NCBI
44	Bolignano D, Donato V, Lacquaniti A, et al: Neutrophil gelatinase-associated lipocalin (NGAL) in human neoplasias: a new protein enters the scene. Cancer Lett. 288:10–16. 2010. View Article : Google Scholar : PubMed/NCBI
45	Masson V, de la Ballina LR, Munaut C, et al: Contribution of host MMP-2 and MMP-9 to promote tumor vascularization and invasion of malignant keratinocytes. FASEB J. 19:234–236. 2005.PubMed/NCBI
46	Jankun J, Aleem AM, Selman SH, Basrur V and Skrzypczak-Jankun E: VLHL plasminogen activator inhibitor spontaneously reactivates from the latent to active form. Int J Mol Med. 23:57–63. 2009.PubMed/NCBI
47	Jankun J, Aleem AM, Specht Z, et al: PAI-1 induces cell detachment, downregulates nucleophosmin (B23) and fortilin (TCTP) in LnCAP prostate cancer cells. Int J Mol Med. 20:11–20. 2007.
48	Jankun J and Skrzypczak-Jankun E: Yin and yang of the plasminogen activator inhibitor. Pol Arch Med Wewn. 119:410–417. 2009.PubMed/NCBI
49	Ravindranath MH, Muthugounder S, Presser N and Viswanathan S: Anticancer therapeutic potential of soy isoflavone, genistein. Adv Exp Med Biol. 546:121–165. 2004. View Article : Google Scholar : PubMed/NCBI
50	Fujisawa S, Atsumi T, Ishihara M and Kadoma Y: Cytotoxicity, ROS-generation activity and radical-scavenging activity of curcumin and related compounds. Anticancer Res. 24:563–569. 2004.PubMed/NCBI
51	Youssef KM, El-Sherbeny MA, El-Shafie FS, Farag HA, Al-Deeb OA and Awadalla SA: Synthesis of curcumin analogues as potential antioxidant, cancer chemopreventive agents. Arch Pharm (Weinheim). 337:42–54. 2004. View Article : Google Scholar : PubMed/NCBI
52	Zingg JM, Hasan ST and Meydani M: Molecular mechanisms of hypolipidemic effects of curcumin. Biofactors. 39:101–121. 2013. View Article : Google Scholar : PubMed/NCBI
53	Menon VP and Sudheer AR: Antioxidant and anti-inflammatory properties of curcumin. Adv Exp Med Biol. 595:105–125. 2007. View Article : Google Scholar : PubMed/NCBI
54	Gafner S, Lee SK, Cuendet M, et al: Biologic evaluation of curcumin and structural derivatives in cancer chemoprevention model systems. Phytochemistry. 65:2849–2859. 2004. View Article : Google Scholar : PubMed/NCBI
55	Guo LY, Cai XF, Lee JJ, et al: Comparison of suppressive effects of demethoxycurcumin and bisdemethoxycurcumin on expressions of inflammatory mediators in vitro and in vivo. Arch Pharm Res. 31:490–496. 2008. View Article : Google Scholar : PubMed/NCBI
56	Handler N, Jaeger W, Puschacher H, Leisser K and Erker T: Synthesis of novel curcumin analogues and their evaluation as selective cyclooxygenase-1 (COX-1) inhibitors. Chem Pharm Bull (Tokyo). 55:64–71. 2007. View Article : Google Scholar : PubMed/NCBI
57	Griesser M, Pistis V, Suzuki T, Tejera N, Pratt DA and Schneider C: Autoxidative and cyclooxygenase-2 catalyzed transformation of the dietary chemopreventive agent curcumin. J Biol Chem. 286:1114–1124. 2011. View Article : Google Scholar : PubMed/NCBI
58	Dong L, Vecchio AJ, Sharma NP, Jurban BJ, Malkowski MG and Smith WL: Human cyclooxygenase-2 is a sequence homodimer that functions as a conformational heterodimer. J Biol Chem. 286:19035–19046. 2011. View Article : Google Scholar
59	Xu YY, Cao Y, Ma H, Li HQ and Ao GZ: Design, synthesis and molecular docking of α,β-unsaturated cyclohexanone analogous of curcumin as potent EGFR inhibitors with antiproliferative activity. Bioorg Med Chem. 21:388–394. 2013.
60	Kolev TM, Velcheva EA, Stamboliyska BA and Spiteller M: DFT and experimental studies of the structure and vibrational spectra of curcumin. Int J Quantum Chem. 102:1069–1079. 2005. View Article : Google Scholar